And Some Of The Stuff Pfizer Lobbied On, In Q4 2017...

Here's the other bookend -- to mine, of Wednesday -- now setting out the bulk of the matters that Pfizer, for its part, lobbied on during the last quarter of 2017.

This is simply a trivial clean up post, then:

. . . .Trans Pacific Partnership Negotiations; Trans-Atlantic trade & Investment Partnership; Canada IP/Trade Issues; South Africa IP Issues; China IP; Indonesia IP; Thailand IP; Korea Pricing Issues; United Nations Health Panel; G7/G20; APEC; OECD; Australia Market -- Size Damages; WTO "Zero for Zero" Pharmaceutical Agreement; NAFTA. . . .

Drug Pricing; Biosimilars Reimbursement; Antibiotic Resistance; Drug Shortages; Reimbursement for products treating Sickle Cell Disease; Creates Act [What is this? I'll come back to it. . . . but Sen. Leahy has a good idea here.]

Medicare Part D; Medicare Part B CMMI Demo; Medicare Part B Reimbursement; Non-Interference; Importation; Prescription Drug Abuse meausres. . . .

Comprehensive Tax Reform; Territorial Systems; Border Adjustability Tax. . . .

Now you know -- have a great weekend -- clear, and in the 50s here now, so I am off on a walkabout.

नमस्ते